

Remarks

The specification has been amended to substitute the current Sequence Listing with the Substitute Sequence Listing filed herewith. The Sequence Listing has been amended only to include the lineage for the present application. No new matter has been added by way of the Substitute Sequence Listing.

In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Substitute Sequence Listing and the computer readable copy of the Substitute Sequence Listing submitted herewith are the same.


Upon entry of the foregoing amendment, claims 1-6, 8, 11-17, 37-40, 42, 47-49, 55, 56, 59, 60, 61, 67-70 and 74-79 are pending in the application, with claims 1 and 11 being the independent claims. Claims 7, 9, 10, 18-36, 41, 43-46, 50-54, 57, 58, 62-66 and 71-73 are sought to be cancelled without prejudice to or disclaimer of the subject matter therein. Claims 1, 8, 11, 12, 15, 37-40, 42, 47 and 59 have been amended. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Conclusion

Prompt and favorable consideration of this Preliminary Amendment is respectfully requested. Applicants believe the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert A. Schwartzman, Ph.D.
Agent for Applicants
Registration No. 50,211

Date: April 5, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600